Evidence for the utility of cfDNA plasma concentrations to predict disease severity in COVID-19: a retrospective pilot study.
Katharina HoeterElmo NeubergerSusanne FischerManuel HerbstEma JuškevičiūtėKira EndersHeidi RossmannMartin F SprinzlPerikles SimonMarc BodensteinMichael SchaeferPublished in: PeerJ (2023)
The results of this observational pilot study show a wide range in cfDNA plasma concentrations in patients with COVID-19 during the first wave of infection and confirm that cfDNA plasma concentrations serve as a predictive biomarker of disease severity in COVID-19.